Evidence map›Paper›PMID 36776673›Full record

ArticleCrohn's & colitis 3602021

Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience.

Guilherme Piovezani Ramos, Badr Al-Bawardy, Manuel Bonfim Braga Neto, Adam C Bledsoe, Kevin P Quinn, Valérie Heron, Maria Alice V Willrich, Amanda Johnson, Victor G Chedid, Nayantara Coelho-Prabhu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Crohn's & colitis 360, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Guilherme Piovezani RamosDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7756-001X
Badr Al-BawardyDivision of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA.
Manuel Bonfim Braga NetoDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Adam C BledsoeDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Kevin P QuinnDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Valérie HeronDivision of Gastroenterology, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada.
Maria Alice V WillrichDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Amanda JohnsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Victor G ChedidDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Nayantara Coelho-PrabhuDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Konstantinos A PapadakisDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Darrell PardiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Sunanda KaneDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-6410-4242
William J TremaineDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Laura RaffalsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5267-2592
David H BruiningDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
William A FaubionDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
William S HarmsenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Edward V LoftusDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-7199-6851

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Certolizumab pegol (CZP) has been successfully used for the treatment of Crohn disease (CD); however, real-world data regarding the utility of CZP trough levels (CTLs) are lacking. We aimed to correlate CTL with CD outcomes and to determine frequency of CZP antibodies. Methods: Retrospective evaluation of all CD patients on maintenance CZP with CTL obtained between 2016 and 2019. Outcomes included: median CTL, presence of anti-CZP antibodies, biochemical response (BR), clinical response (CR), radiologic response (RR), radiologic healing (RH), and mucosal healing (MH). Results: Seventy-seven CD patients were included. Median CTL was 18.9 µg/mL (interquartile range, 7.6-35.4). Twenty-three patients (27.3%) had positive antibody levels, with lower median CTL compared to patients with no antibodies (0.0 vs 29.8; Conclusions: Higher CTL was significantly associated with CR and RR. The rate of CZP antibodies was 27.3%. Our data suggest maintenance CTL of ≥19 µg/mL should be achieved in order to optimize outcomes in clinical practice.

Indexed as

certolizumab pegolCrohn diseaseinflammatory bowel diseasetherapeutic drug monitoring

Identifiers

PMID36776673
PMCPMC9802288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.